Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis
申请人:Dodge Jeffrey Alan
公开号:US20110166182A1
公开(公告)日:2011-07-07
The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof.
本发明涉及公式(A)的化合物或其药学上可接受的盐;以及公式(I)的化合物或其药学上可接受的盐。
Selective estrogen receptor modulator for the treatment of osteoarthritis
申请人:Dodge Jeffrey Alan
公开号:US08476300B2
公开(公告)日:2013-07-02
The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof.
本发明涉及以下化合物(A)或其药学上可接受的盐;以及以下化合物(I)或其药学上可接受的盐。
HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND
申请人:UBE INDUSTRIES, LTD.
公开号:EP2940013B1
公开(公告)日:2018-02-21
SALT OF HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND
申请人:UBE Industries, Ltd.
公开号:EP3162801B1
公开(公告)日:2020-07-22
[EN] SELECTIVE ESTROGEN REPECTOR MODULATOR FOR THE TREATMENT OF OSTEOARTHRITIS<br/>[FR] MODULATEUR SÉLECTIF DES RÉCEPTEURS D'OESTROGÈNES